IGCC 2025 | 复宏汉霖H药 汉斯状®胃癌领域最新研究结果入选

H药 汉斯状^®是全球首个获批一线治疗小细胞肺癌的抗PD-1单抗，已在中国、欧洲和东南亚等30多个国家和地区获批上市。截至目前，H药已获批用于治疗鳞状非小细胞肺癌（sqNSCLC）、广泛期小细胞肺癌（ES-SCLC）、食管鳞状细胞癌（ESCC）和非鳞状非小细胞肺癌（nsNSCLC）。聚焦肺癌和消化道肿瘤等全球高发癌种，复宏汉霖在全球同步开展10余项以H药为核心的免疫联合疗法临床研究，于中国、美国、日本、土耳其、波兰、格鲁吉亚等国家和地区累计入组逾4900人。消化道肿瘤方面，公司持续探索结直肠癌、胃癌等领域治疗研究。其中，H药联合化疗用于新辅助/辅助治疗胃癌III期临床研究正在积极推进，H药联合贝伐珠单抗联合化疗用于一线治疗转移性结直肠癌（mCRC）患者的国际多中心临床研究（ASTRUM-015）进入III期临床阶段并于中国、印度尼西亚和日本完成首例受试者给药，H药 汉斯状^®有望成为全球首个治疗non-MSI-H mCRC的抗PD-1单抗。

入选此次IGCC 2025大会的两项H药胃癌领域研究如下：

Henlius to Present Latest Results of Serplulimab in Gastric Cancer at IGCC 2025

The 16th International Gastric Cancer Congress (IGCC 2025), organized by the International Gastric Cancer Association (IGCA), will take place in Amsterdam, the Netherlands, from May 7 to 10, 2025. The latest results on Henlius’ self-developed innovative anti-PD-1 monoclonal antibody (mAb) HANSIZHUANG (serplulimab, trade name: Hetronifly^® in Europe) will be presented at the congress. Among them, a phase 2 study evaluating serplulimab combined with concurrent chemoradiotherapy as neoadjuvant treatment for resectable esophagogastric junction adenocarcinoma will be orally presented.

HANSIZHUANG is the world’s first anti-PD-1 mAb for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) and has been approved for marketing in over 30 countries and regions, including China, Europe and Southeast Asia. Up to date, it has been approved for the treatment of squamous non-small cell lung cancer (sqNSCLC), ES-SCLC, esophageal squamous cell carcinoma (ESCC) and non-squamous non-small cell lung cancer (nsNSCLC). Focus on lung and gastrointestinal cancer, the synergy of HANSIZHUANG with in-house products of the company and innovative therapies are being actively promoted. The company has initiated over 10 clinical trials on immuno-oncology combination therapies in a wide variety of indications with more than 4,900 subjects enrolled in China, the U.S., Japan, Turkey, Poland, Georgia and other countries and regions. In the field of gastrointestinal cancers, the company continues to explore therapeutic research in colorectal cancer and gastric cancer. The company is actively advancing a phase 3 clinical trial of HANSIZHUANG plus chemotherapy as neoadjuvant/adjuvant therapy for gastric cancer. The phase 3 stage of the international multi-centre clinical trial (ASTRUM-015) of serplulimab in combination with bevacizumab and chemotherapy in first-line treatment of metastatic colorectal cancer (mCRC) has dosed the first patients in China, Indonesia and Japan, potentially making it the first anti-PD-1 mAb in non-MSI-H mCRC worldwide.

Details of the results of serplulimab to be presented at IGCC 2025 are as follows:

媒体：PR@Henlius.com

投资者：IR@Henlius.com